{
    "doi": "https://doi.org/10.1182/blood.V120.21.4868.4868",
    "article_title": "Obinutuzumab (GA101) Displays Higher Efficiency Than Rituximab in a Follicular Lymphoma 3D Model ",
    "article_date": "November 16, 2012",
    "session_type": "Lymphoma - Pre-Clinical - Chemotherapy and Biologic Agents",
    "abstract_text": "Abstract 4868 Follicular lymphomas (FL) account for 35\u201340% of all adult lymphomas. Treatment typically involves chemotherapy combined with the anti-CD20 monoclonal antibody (MAb) rituximab (RTX). The development of type II anti-CD20 MAb obinutuzumab (GA101) aims to improve treatment further. Using FL cells, here we showed that RTX and GA101 displayed similar efficiency towards 2D culture. However, 2D culture does not mimic tumor spatial organization and conventional 2D models do not reflect the effects of MAbs seen from preclinical and in vivo studies. Thus, we created a NHL 3D culture system, the so-called multicellular aggregates of lymphoma cells (MALC), and compared RTX with GA101 activity. Our result showed that both MAbs displayed greater bioactivity towards FL cells in 3D culture compared to 2D culture. Moreover, we observed that GA101 was more effective than RTX in inhibiting tumor growth through induction of apoptosis, lysosomal cell death and senescence. GA101 was also more effective than RTX in inhibiting intracellular signaling pathways such as mTOR, Akt, PLCgamma and Syk. Altogether, our study demonstrates that spatial organization strongly influences response to MAbs treatment. Additionally, we provide evidences that GA101 is more effective than RTX in inhibiting FL development in MALC model, which suggests the possibility for better patient treatment with GA101. Disclosures: Decaup: roche: Employment, Research Funding. Klein: Roche Glycart AG: Employment. Varoqueaux: Roche S.A.S: Employment. Bezombes: Roche: Research Funding.",
    "topics": [
        "follicular lymphoma",
        "obinutuzumab",
        "rituximab",
        "lymphoma",
        "monoclonal antibodies",
        "cd20 antigens",
        "chemotherapy regimen",
        "mtor serine-threonine kinases",
        "neoplasms",
        "proto-oncogene proteins c-akt"
    ],
    "author_names": [
        "Emilie Decaup",
        "Christine Jean, PhD",
        "Camille Laurent, MD",
        "Pauline Gravelle",
        "Se\u0301verine Fruchon, PhD",
        "Florence Capilla",
        "Alain Marrot",
        "Talal AlSaati, MD",
        "Franc\u0327ois-Xavier Frenois",
        "Guy Laurent, MD PHD",
        "Christian Klein, PhD",
        "Jean-Jacques Fournie\u0301, PhD",
        "Nathalie Varoqueaux, MD PHD",
        "Christine Bezombes, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Emilie Decaup",
            "author_affiliations": [
                "Universite\u0301 Paul Sabatier Toulouse III, CRCT INSERM U1037 CNRS ERL 5294, Toulouse, France, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Christine Jean, PhD",
            "author_affiliations": [
                "Department of Reproductive Medicine, Moores UCSD Cancer Center, La Jolla, CA, USA, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Camille Laurent, MD",
            "author_affiliations": [
                "Laboratoire d'anatomopathologie, CHU Purpan, Toulouse, France, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pauline Gravelle",
            "author_affiliations": [
                "Universite\u0301 Paul Sabatier Toulouse III, CRCT INSERM U1037 CNRS ERL 5294, Toulouse, France, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Se\u0301verine Fruchon, PhD",
            "author_affiliations": [
                "Universite\u0301 Paul Sabatier Toulouse III, CPTP UMR 1043, Toulouse, France, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Florence Capilla",
            "author_affiliations": [
                "histopathology, InSERM-US006 ANEXPLO/CREFRE, toulouse, France, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alain Marrot",
            "author_affiliations": [
                "Histopathology, INSERM-US006 ANEXPLO/CREFRE, Toulouse, France, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Talal AlSaati, MD",
            "author_affiliations": [
                "Histopathology, INSERM-US006 ANEXPLO/CREFRE, toulouse, France, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Franc\u0327ois-Xavier Frenois",
            "author_affiliations": [
                "Service Anatomie Pathologique, toulouse, France, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guy Laurent, MD PHD",
            "author_affiliations": [
                "Hematology, CHU Purpan, Toulouse, France, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Christian Klein, PhD",
            "author_affiliations": [
                "Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jean-Jacques Fournie\u0301, PhD",
            "author_affiliations": [
                "Universite\u0301 Paul Sabatier Toulouse III, CRCT INSERM U1037 CNRS ERL5294, Toulouse, France, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Nathalie Varoqueaux, MD PHD",
            "author_affiliations": [
                "Roche S.A.S, Boulogne-Billancourt Cedex, France, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Christine Bezombes, PhD",
            "author_affiliations": [
                "Universite\u0301 Paul Sabatier Touluse III, CRCT INSERM U1037 CNRS 5294, Toulouse, France"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-21T18:39:43",
    "is_scraped": "1"
}